Development of an Electronic Health Record–Based Clinical Decision Support Tool for Patients With Lynch Syndrome
Kelsey S. Lau-Min, Joseph Bleznuck, Colin Wollack, Danielle B. McKenna, Jessica M. Long, Anna P. Hubert, Mariah Johnson, Shavon E. Rochester, Gillain Constantino, Christina Dudzik, Abigail Doucette, Kirk Wangensteen, Susan M. Domchek, Jeffrey Landgraf, Jessica Chen, Katherine L. Nathanson, Bryson W. Katona- General Medicine
PURPOSE
To develop an electronic health record (EHR)–based clinical decision support (CDS) tool to promote guideline-recommended cancer risk management among patients with Lynch syndrome (LS), an inherited cancer syndrome that confers an increased risk of colorectal and other cancer types.
MATERIALS AND METHODS
We conducted a cross-sectional study to determine the baseline prevalence and predictors of guideline-recommended colonic surveillance and annual genetics program visits among patients with LS. Multivariable log-binomial regressions estimated prevalence ratios (PRs) of cancer risk management adherence by baseline sociodemographic and clinical characteristics. These analyses provided rationale for the development of an EHR-based CDS tool to support patients and clinicians with LS-related endoscopic surveillance and annual genetics program visits. The CDS leverages an EHR platform linking discrete genetic data to LS Genomic Indicators, in turn driving downstream clinician- and patient-facing CDS.
RESULTS
Among 323 patients with LS, cross-sectional adherence to colonic surveillance and annual genetics program visits was 69.3% and 55.4%, respectively. Patients with recent electronic patient portal use were more likely to be adherent to colonic surveillance (PR, 1.67; 95% CI, 1.11 to 2.52). Patients more recently diagnosed with LS were more likely to be adherent to annual genetics program visits (PR, 0.58; 95% CI, 0.44 to 0.76 for 2-4 years; PR, 0.62; 95% CI, 0.51 to 0.75 for ≥4 compared with <2 years). Our EHR-based CDS tool is now active for 421 patients with LS throughout our health system.
CONCLUSION
We have successfully developed an EHR-based CDS tool to promote guideline-recommended cancer risk management among patients with LS.